Course outline
Module 1
Module 1: Origins and History of Microdosing
Origins and History of Microdosing
Knowledge check
Q1. Which researcher is most commonly credited with coining the term 'microdosing' in the context of psychedelic use?
- A. Albert Hofmann
- B. Timothy Leary
- C. James Fadiman ✓
- D. Stanislav Grof
Why: James Fadiman, a psychologist who studied psychedelics, popularized the term 'microdosing' in the early 2010s through his work and his 2011 book 'The Psychedelic Explorer's Guide', which described sub-perceptual doses of LSD and related compounds.
Q2. Albert Hofmann, the Swiss chemist who first synthesized LSD in 1938, discovered its psychoactive effects in which year?
- A. 1938
- B. 1943 ✓
- C. 1951
- D. 1960
Why: Hofmann accidentally absorbed a small amount of LSD in 1943 and experienced its effects, leading to the first intentional self-experiment on April 19, 1943, now celebrated as 'Bicycle Day'.
Q3. Which of the following was a key concern that led to the restriction of psychedelic research in the United States during the 1960s and 1970s?
- A. Lack of any measurable effects in human subjects
- B. Concerns over recreational use, public perception, and political pressure ✓
- C. Discovery that the compounds were chemically unstable
- D. The discovery that psychedelics caused permanent physical damage in all users
Why: Recreational use spread widely in the 1960s, provoking public alarm and political pressure, which led to the Controlled Substances Act of 1970 and effectively halted most clinical psychedelic research for decades.
Q4. Before the modern microdosing trend, what was an early historical example of people taking very small amounts of psychoactive substances for their effects?
- A. Fasting rituals in ancient Egypt
- B. Swiss physicians and workers taking tiny doses of Hofmann's compounds, and Eastern cultures using low doses of psychoactive plants like betel
- C. Taking aspirin before surgery in medieval Europe
- D. Ingesting mercury for medicinal purposes in Renaissance Italy only
Q5. Which community of users was especially influential in popularizing microdosing in the 2010s, particularly in Silicon Valley and tech circles?
- A. Professional athletes seeking performance enhancement
- B. Academic neuroscientists studying cognition
- C. Entrepreneurs and professionals seeking productivity and creativity benefits ✓
- D. Religious leaders using sacramental doses
Why: Reports from entrepreneurs and tech workers who claimed improved focus, creativity, and productivity from sub-perceptual doses helped spread microdosing into mainstream culture, although many of these claims remain anecdotal and lack rigorous scientific support.
Module 2
Module 2: Pharmacology of Low-Dose Psychedelics
Pharmacology of Low-Dose Psychedelics
Knowledge check
Q1. Which primary receptor is most strongly associated with the psychedelic effects of classic serotonergic psychedelics such as LSD and psilocin?
- A. Dopamine D2 receptor
- B. Serotonin 5-HT2A receptor ✓
- C. GABA-A receptor
- D. Mu-opioid receptor
Why: Agonism at the 5-HT2A receptor is considered the key mechanism behind the perceptual and cognitive effects of classic psychedelics. Activity at other receptors, such as 5-HT1A, may modulate the overall experience.
Q2. What is the main active compound produced in the body after ingesting psilocybin-containing mushrooms?
- A. Mescaline
- B. DMT
- C. Psilocin ✓
- D. Ibogaine
Why: Psilocybin is a prodrug that is dephosphorylated in the body to psilocin, which is the compound that acts on serotonin receptors to produce psychedelic effects.
Q3. Which term describes the practice of taking a very small, sub-perceptual dose of a psychedelic, typically about one tenth of a full dose?
- A. Titration
- B. Microdosing ✓
- C. Potentiation
- D. Tapering
Why: Microdosing refers to taking sub-perceptual amounts of a psychedelic substance, generally small enough that the user does not experience noticeable hallucinations or altered consciousness.
Q4. Why is the scientific evidence for microdosing benefits considered limited as of now?
- A. Microdosing has been proven to be entirely ineffective in all studies
- B. Most evidence is anecdotal or from small, uncontrolled studies, and placebo effects are hard to rule out ✓
- C. Psychedelics are chemically unable to act at low doses
- D. Regulatory agencies have banned all human research on microdosing
Why: Much of the popular support for microdosing comes from self-reports and surveys. Controlled, blinded trials are few and small, making it difficult to separate genuine pharmacological effects from expectancy and placebo responses.
Q5. Which pharmacological property of LSD and psilocin contributes to their long duration of action relative to their dose?
- A. They are rapidly eliminated by the liver within minutes
- B. They are highly water-soluble and excreted unchanged in urine
- C. They have high receptor affinity and their effects persist well beyond their plasma half-life, partly due to receptor signaling dynamics ✓
- D. They irreversibly bind to serotonin transporters
Why: Classic psychedelics produce effects lasting many hours even though their plasma half-lives are much shorter. This is attributed to prolonged downstream signaling and receptor-level dynamics, which is one reason microdosing schedules are designed around intervals of a day or more.
Module 3
Module 3: Evidence from Clinical and Research Studies
Evidence from Clinical and Research Studies
Knowledge check
Q1. What is the typical dose range used in microdosing studies of psilocybin or LSD?
- A. A full recreational dose, roughly 1-3 grams of dried mushrooms or 100 micrograms of LSD
- B. A sub-perceptual dose, roughly 5-10% of a full dose, that does not produce noticeable hallucinations ✓
- C. A dose sufficient to cause a mystical experience lasting several hours
- D. A dose high enough to produce temporary dissociation but without visual effects
Why: Microdosing refers to sub-perceptual amounts, typically around 5-10% of a full psychedelic dose, chosen so the user does not experience noticeable psychedelic effects. Full recreational or therapeutic doses are much larger.
Q2. Which statement best describes the state of clinical evidence on microdosing's benefits?
- A. Large randomized controlled trials have confirmed improved mood and creativity
- B. Evidence is mostly anecdotal and from self-reported surveys, with few controlled placebo-blinded studies ✓
- C. Multiple placebo-controlled trials have shown microdosing outperforms antidepressants
- D. Microdosing has been proven to cause lasting changes in brain structure in humans
Why: Much of the popularity of microdosing rests on self-report surveys and anecdotes. Placebo-controlled, blinded studies are scarce, and the ones that exist often show effects similar to placebo, so strong claims are not yet supported.
Q3. Why is blinding important in microdosing research?
- A. It keeps participants from knowing the dose so researchers can increase it without consent
- B. Because sub-perceptual doses can be noticed by participants, expectations may influence reported outcomes unless the study is blinded and uses placebos ✓
- C. It prevents participants from discussing the study with others who might be at risk
- D. It is only required for legal reasons and has no effect on results
Why: Participants who believe they took a psychedelic may report improved mood or creativity due to expectation alone. Blinding and placebo controls separate the pharmacological effect from expectancy and placebo responses.
Q4. Which outcome measure is most often used in clinical studies of psychedelics for depression?
- A. Standardized rating scales such as the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale ✓
- B. Blood glucose levels measured before and after dosing
- C. The number of social media posts participants make about their mood
- D. Hours of sleep recorded by a smartwatch as the only primary outcome
Why: Clinical trials of psychedelics for depression typically use validated clinician-rated or self-rated scales such as HAM-D or MADRS to quantify symptom change in a standardized, comparable way.
Q5. What is a key limitation of much of the existing microdosing research?
- A. Sample sizes are often small and studies are short, limiting conclusions about long-term safety and efficacy ✓
- B. Researchers have studied only elderly participants with no other health conditions
- C. All studies have used the same validated psychedelic at identical doses
- D. Microdosing studies have never been published in peer-reviewed journals
Why: Many microdosing studies involve small, short-term samples and often rely on self-report. This makes it hard to draw firm conclusions about durability of effects, safety, or how results generalize to wider populations.
Module 4
Module 4: Microdosing in Popular and Online Culture
Microdosing in Popular and Online Culture
Knowledge check
Q1. Which term is most commonly used to describe taking very small, sub-perceptual doses of a psychedelic substance on a regular schedule?
- A. Megadosing
- B. Microdosing ✓
- C. Binge dosing
- D. Titration
Why: Microdosing refers to taking sub-perceptual amounts of a psychedelic, typically a fraction of a full recreational dose, usually every few days, so that the user does not experience noticeable hallucinations or intoxication.
Q2. Which online platform played a major role in spreading first-person accounts and self-experimentation stories about microdosing in the 2010s?
- A. LinkedIn
- B. Reddit ✓
- C. Pinterest
- D. Goodreads
Why: Subreddits and forums on Reddit became central hubs where users shared dosing schedules, personal anecdotes, and mood or productivity reports, helping popularize microdosing among a broad audience.
Q3. Which phrase best captures a common claim about microdosing in popular culture?
- A. It reliably cures clinical depression in all users.
- B. It is said to boost creativity, focus, and mood, though these claims are largely anecdotal.
- C. It has been approved by regulators as a standard treatment.
- D. It produces the same effects as a full psychedelic trip, only shorter.
Q4. What is a key reason scientists urge caution when evaluating popular microdosing stories?
- A. Microdosing has been proven to be completely ineffective in every study.
- B. Many reported benefits come from self-reports and uncontrolled settings, and placebo effects are hard to rule out.
- C. Microdosing is only studied in animals, so human data does not exist.
- D. Online users are required by law to report only negative outcomes.
Q5. Why did microdosing gain prominence in Silicon Valley and tech circles according to popular media coverage?
- A. It was officially endorsed by major technology companies as a workplace benefit.
- B. It was promoted as a way to enhance productivity and creative thinking, which fit a culture focused on performance.
- C. It was required for employment in certain engineering roles.
- D. It was the only treatment available for workplace stress at the time.
Module 5
Module 5: Self-Experimentation and Anecdotal Reports
Self-Experimentation and Anecdotal Reports
Knowledge check
Q1. Which of the following best describes an anecdotal report in the context of microdosing research?
- A. A randomized, placebo-controlled trial with blinded participants
- B. A first-person account of subjective experience, typically unverified and uncontrolled ✓
- C. A meta-analysis combining data from multiple peer-reviewed studies
- D. A laboratory measurement of drug concentration in blood plasma
Why: Anecdotal reports are personal, first-person accounts of experiences. They are valuable for generating hypotheses but are typically unverified and lack controls, so they cannot establish causation.
Q2. What is a major limitation of self-experimentation when evaluating whether microdosing improves mood?
- A. Participants always report exaggerated benefits because of the drug's chemical properties
- B. Expectancy effects and the placebo response are difficult to separate from the true effect ✓
- C. Self-experimenters are legally prohibited from recording their own data
- D. Results cannot be repeated by anyone other than the original experimenter
Why: When people know they are taking a substance and expect benefits, expectancy and placebo effects can produce apparent improvements. Without blinding and a control condition, it is hard to attribute changes to the substance itself.
Q3. Why is confirmation bias a concern in microdosing self-experiments?
- A. It causes the body to metabolize substances more slowly
- B. It leads people to notice and remember experiences that fit their expectations while overlooking contradictory ones ✓
- C. It makes participants unwilling to keep any written record of their dosing
- D. It guarantees that all reported side effects are fabricated
Why: Confirmation bias is the tendency to favor information that supports existing beliefs. A self-experimenter who expects microdosing to help may selectively emphasize good days and discount bad ones, distorting their conclusions.
Q4. What does the term 'n-of-1 trial' refer to in the context of self-experimentation?
- A. A study in which a single individual serves as both the experimental and control condition through systematic, repeated comparisons ✓
- B. A study with exactly one participant who receives no treatment at all
- C. A large trial in which only one outcome measure is recorded
- D. A survey completed by exactly one researcher about their own publications
Why: An n-of-1 trial uses a single person and alternates between treatment and control periods, often with blinding, to produce more rigorous individual-level evidence than a single anecdote.
Q5. Which practice would most improve the reliability of a personal microdosing self-experiment?
- A. Relying on memory to summarize how you felt at the end of each month
- B. Recording daily symptoms in advance of the study and using blinded or randomized dosing schedules ✓
- C. Increasing the dose each week to see how the body responds
- D. Sharing the experience only on social media to gather feedback
Why: Prospective, structured logging reduces recall bias, and blinded or randomized dosing (such as using placebo days unknown to the experimenter) helps separate the substance's effects from expectation, making conclusions more trustworthy.
Module 6
Module 6: Commercial Hype and the Wellness Industry
Commercial Hype and the Wellness Industry
Knowledge check
Q1. Which of the following best describes the term 'microdosing' as it is typically used in popular wellness culture?
- A. Taking a full recreational dose of a psychedelic once a month to achieve lasting spiritual insight
- B. Taking a very small, sub-perceptual dose of a psychedelic substance on a regular schedule, often without noticeable intoxicating effects
- C. Using a prescription medication at the lowest dose approved by a physician for a specific condition
- D. Consuming high-potency supplements in short bursts to boost daily energy levels
Q2. Why do wellness marketers often use anecdotal testimonials when promoting microdosing products or programs?
- A. Because testimonials are required by law for all psychoactive products
- B. Because personal stories are emotionally compelling and can substitute for controlled evidence that many products lack
- C. Because randomized controlled trials have already proven microdosing effective for most conditions
- D. Because regulators specifically approve testimonials as a substitute for clinical data
Q3. Which feature is a common warning sign of commercial hype in the wellness industry?
- A. Clear disclosure of the study size and limitations of the research cited
- B. Promises of rapid, dramatic, and universal benefits supported mainly by vague claims of 'science-backed' results
- C. Recommendations to consult a healthcare provider before starting a new regimen
- D. Transparent information about sourcing, dosing methods, and potential side effects
Q4. A microdosing product claims to be 'clinically proven' to boost creativity. What is the most appropriate skeptical response?
- A. Accept the claim, since the word 'clinically' guarantees the results were peer-reviewed
- B. Ask what the specific study design, sample size, controls, and publication status were, since 'clinically proven' is often used loosely
- C. Assume the claim is accurate because creativity is impossible to measure, so no study could disprove it
- D. Conclude the product is dangerous and avoid all discussion of the topic
Q5. Why is the placebo effect particularly important to consider when evaluating claims about microdosing benefits?
- A. Because placebo effects only occur in people who already take prescription medications
- B. Because expectations and the belief that one is taking a special substance can produce reported improvements unrelated to the substance itself
- C. Because placebo effects prove that any substance must be active if people report benefits
- D. Because placebo effects have been shown to be permanent and always cause harm
Module 7
Module 7: Regulation, Risks and Ethical Questions
Regulation, Risks and Ethical Questions
Knowledge check
Q1. Which legal status do psilocybin and LSD currently hold in most countries, including the United States under the Controlled Substances Act?
- A. Schedule V controlled substances with medical prescriptions available
- B. Schedule I controlled substances with no accepted medical use under current federal law
- C. Unregulated dietary supplements sold without restriction
- D. Schedule III substances available only for veterinary use
Q2. What is a key ethical concern raised by researchers studying microdosing in everyday settings?
- A. Microdosing has been proven to cause immediate physical addiction in all users
- B. Self-reported benefits are highly susceptible to placebo effects and expectancy bias, making claims hard to verify
- C. Microdosing is only available to people with a formal medical diagnosis
- D. Researchers are prohibited from recruiting volunteers for any psychedelic study
Q3. Why do many clinical trials of microdosing use a double-blind, placebo-controlled design?
- A. To ensure participants know exactly which dose they are receiving
- B. To reduce the influence of expectations on outcomes, so effects can be attributed to the substance rather than belief
- C. Because placebo-controlled designs are required only for stimulant drugs
- D. To increase the potency of the active compound during the study
Q4. Which of the following is a commonly cited risk of microdosing, even at low doses?
- A. Guaranteed permanent improvement in mood
- B. Possible interactions with prescription medications such as SSRIs, and the risk of obtaining unregulated or mislabeled substances
- C. Complete elimination of the need for sleep
- D. Automatic protection against all forms of mental illness
Q5. What does the principle of informed consent require in the context of microdosing research or self-experimentation?
- A. Participants should be told only the potential benefits to encourage enrollment
- B. Participants should receive accurate information about known and unknown risks, legal status, and their right to withdraw at any time
- C. Consent is unnecessary when the substance is considered low dose
- D. Only the researcher's institution needs to approve the study, not the participant